Free tool
FAERS Monitor: Vyvanse
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021977 or its brand name (Vyvanse, Lisdexamfetamine Dimesylate). Reports on generic versions are filed under their own applications.
Reports
33,465
Serious
13,613
41% of reports
Hospitalization
3,997
Death reported
307
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective4,768
- fatigue2,100
- off label use2,063
- anxiety1,851
- headache1,805
- nausea1,597
- product availability issue1,583
- insomnia1,505
- depression1,415
- feeling abnormal1,368
- product use issue1,335
- disturbance in attention1,284
- no adverse event1,206
- product quality issue1,205
- intentional overdose1,155
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2007 | 300 |
| 2008 | 974 |
| 2009 | 1,147 |
| 2010 | 431 |
| 2011 | 377 |
| 2012 | 415 |
| 2013 | 502 |
| 2014 | 1,419 |
| 2015 | 2,219 |
| 2016 | 3,132 |
| 2017 | 1,872 |
| 2018 | 1,904 |
| 2019 | 1,777 |
| 2020 | 1,804 |
| 2021 | 1,700 |
| 2022 | 2,503 |
| 2023 | 3,169 |
| 2024 | 3,256 |
| 2025 | 2,700 |
| 2026 | 1,864 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,020,694 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product availability issueSignal | 1,583 | 46.9 | 44.6 | 66,176 |
| disturbance in attentionSignal | 1,284 | 15.3 | 14.5 | 16,785 |
| intentional overdoseSignal | 1,155 | 11.5 | 10.9 | 10,905 |
| product quality issueSignal | 1,205 | 5.6 | 5.3 | 4,557 |
| product use issueSignal | 1,335 | 4.5 | 4.3 | 3,624 |
| no adverse eventSignal | 1,206 | 4.2 | 4.0 | 2,948 |
| anxietySignal | 1,851 | 4.1 | 3.9 | 4,380 |
| depressionSignal | 1,415 | 3.9 | 3.7 | 3,098 |
| feeling abnormalSignal | 1,368 | 3.6 | 3.4 | 2,584 |
| insomniaSignal | 1,505 | 3.6 | 3.4 | 2,796 |
| drug ineffectiveSignal | 4,768 | 2.3 | 2.2 | 3,634 |
| headache | 1,805 | 1.8 | 1.7 | 674 |
| fatigue | 2,100 | 1.7 | 1.6 | 622 |
| off label use | 2,063 | 1.5 | 1.4 | 336 |
| nausea | 1,597 | 1.3 | 1.2 | 94 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.